<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1643">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05139771</url>
  </required_header>
  <id_info>
    <org_study_id>CLI-E033</org_study_id>
    <nct_id>NCT05139771</nct_id>
  </id_info>
  <brief_title>EndoArt® Implantation in Subjects With Chronic Corneal Edema</brief_title>
  <official_title>An Open-label Multicenter Phase 2 Clinical Safety Investigation of the EndoArt® Implantation in Subjects With Chronic Corneal Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eye-yon Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eye-yon Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The EndoArt® is intended to be used as an endothelial prosthesis in patients with chronic&#xD;
      corneal edema.The EndoArt® (Artificial Endothelial layer) is a permanent implant, constructed&#xD;
      of a clear, transparent, foldable, biologically compatible copolymer of hydroxyethyl&#xD;
      methacrylate and methyl methacrylate. The peripheral surface of the EndoArt® has either one&#xD;
      or more marks, to ensure the correct orientation of the implant. The device serves as a&#xD;
      physical barrier blocking the influx of water from the AC of the eye into the cornea due to&#xD;
      dysfunctional corneal endothelial layer. Together with evaporation from the anterior surface&#xD;
      of the cornea it maintains corneal hydration and clarity.&#xD;
&#xD;
      The EndoArt® device is CE marked approved (approved for marketing by the European regulatory&#xD;
      authority).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, multicenter, open-label, phase 2 clinical investigation&#xD;
      assessing safety of EndoArt® implantation, in subjects with chronic corneal edema. Safety&#xD;
      will be assessed by evaluating the rate of adverse events and adverse device effects&#xD;
      throughout the study period. Exploratory efficacy endpoints will be assessed by measuring the&#xD;
      change in corneal thickness from baseline, change in pain score from baseline and changes in&#xD;
      visual acuity. Time to, and rate of, post-surgical rebubbling to facilitate adhesion of the&#xD;
      device will be explored.&#xD;
&#xD;
      Subjects with chronic corneal edema that meet the inclusion/exclusion criteria will be the&#xD;
      study target population. The study will encompass a total of up to 80 subjects who will&#xD;
      complete the Protocol follow-up schedule. For the Primary endpoint, the frequency and&#xD;
      severity of device related adverse events, from patient entry through the 6-month follow-up&#xD;
      period will be analyzed. Adverse events will be assessed on a continuous basis and will&#xD;
      continue to be collected for 12 months.&#xD;
&#xD;
      This clinical investigation is conducted in up to 12 (twelve) clinical sites in Europe&#xD;
      (Germany, France, and Netherlands), Mexico, India and Israel. Additional sites may be&#xD;
      considered.&#xD;
&#xD;
      This clinical investigation has been designed to provide continuous clinical evidence for the&#xD;
      EndoArt® as part of its clinical follow up program.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The frequency of device related adverse events (safety)</measure>
    <time_frame>12 months</time_frame>
    <description>Adverse events will be assessed on a continuous basis from baseline until follow-ups completion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The severity of device related adverse events (safety).</measure>
    <time_frame>12 months</time_frame>
    <description>Adverse events will be assessed on a continuous basis from baseline until follow-ups completion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in central corneal thickness (CCT) postoperatively.</measure>
    <time_frame>6 months</time_frame>
    <description>Central Corneal Thickness (pachymetry) will be measured by anterior segment Optical Coherence Tomography (OCT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of primary post-surgical detachment of the device.</measure>
    <time_frame>12 months</time_frame>
    <description>Post implantation device detachment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of rebubbling post-op.</measure>
    <time_frame>12 months</time_frame>
    <description>Number of times that post implantation re-bubbling is done</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Best Corrected Distance Visual Acuity (BCDVA) from baseline.</measure>
    <time_frame>12 months</time_frame>
    <description>Visual acuity will be measured with ETDRS format charts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ocular pain score as assessed by a Visual Analogue Scale (VAS) from baseline.</measure>
    <time_frame>12 months</time_frame>
    <description>VAS is a horizontal line, 0-100 mm. VAS score is determined by measuring in millimeters from the left hand end of the line to the point that the subject marks.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Corneal Edema</condition>
  <arm_group>
    <arm_group_label>EndoArt® Artificial Endothelial Layer</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>EndoArt® is intended to be used as an endothelial prosthesis in patients with chronic corneal edema. One arm - all subjects will be implanted with EndoArt®.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>THE ENDOART® IMPLANTATION (Artificial Endothelial layer)</intervention_name>
    <description>Implantation of EndoArt® is similar to other anterior segment surgical procedures such as DSAEK/DMEK.</description>
    <arm_group_label>EndoArt® Artificial Endothelial Layer</arm_group_label>
    <other_name>DSAEK</other_name>
    <other_name>DMEK</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Individuals must meet the following inclusion criteria at screening visit:&#xD;
&#xD;
          1. Male or Female subjects 40-85 years of age.&#xD;
&#xD;
          2. Have chronic corneal edema (for a minimum of 3 months) secondary to endothelial&#xD;
             dysfunction.&#xD;
&#xD;
          3. Have corneal thickness &gt;600μm by OCT.&#xD;
&#xD;
          4. Have best corrected distance visual acuity 6/19 (20/63) or worse (equivalent ETDRS= 60&#xD;
             letters) with subjective symptoms of impaired visual function.&#xD;
&#xD;
          5. Subject with posterior pseudophakia and stable IOL.&#xD;
&#xD;
          6. Willing and able to understand and sign informed consent prior to any study related&#xD;
             procedure.&#xD;
&#xD;
          7. Willing and able to follow study instructions (e.g., to lay on one's back for 4 hours&#xD;
             post op), able to self-administer or have caregiver available to administer eyedrops&#xD;
             as required by the protocol for the duration of the study, and able to attend study&#xD;
             visits/assessments for the duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Individuals for participation will be ineligible for the study if any of the following&#xD;
        conditions apply:&#xD;
&#xD;
          1. History of ocular Herpetic keratitis.&#xD;
&#xD;
          2. Scarred cornea resulting in visual impairment with intact endothelium (cell density ≥&#xD;
             1500).&#xD;
&#xD;
          3. History of posterior vitrectomy.&#xD;
&#xD;
          4. Post PKP&#xD;
&#xD;
          5. Have an irregular posterior cornea (e.g., post trauma).&#xD;
&#xD;
          6. Have a current infection of the cornea.&#xD;
&#xD;
          7. Have band keratopathy and/or limbal stem cell deficiency.&#xD;
&#xD;
          8. Have clinically severe dry eye disease which needs more than 4 drops of lubricant per&#xD;
             day.&#xD;
&#xD;
          9. Phthisis bulbi or subject is at risk of developing phthisis.&#xD;
&#xD;
         10. Subject with medically uncontrolled high intra ocular pressure.&#xD;
&#xD;
         11. Aphakia.&#xD;
&#xD;
         12. Anterior chamber IOL or fixated anterior chamber IOL.&#xD;
&#xD;
         13. Pseudophakodonesis.&#xD;
&#xD;
         14. Have large iris defect which could compromise intraoperative air bubble formation&#xD;
&#xD;
         15. Have undergone corneal refractive surgery.&#xD;
&#xD;
         16. History of neurotrophic cornea.&#xD;
&#xD;
         17. History of recurrent corneal erosion or persistent epithelial defect.&#xD;
&#xD;
         18. IridoCorneal Endothelial (ICE) Syndrome or any rare disease/ syndrome creating&#xD;
             anatomical or physiological anomalies of the anterior chamber (e.g., corectopia).&#xD;
&#xD;
         19. Recurrent posterior, intermediate or anterior uveitis.&#xD;
&#xD;
         20. Subject receiving regular intravitreal injection&#xD;
&#xD;
         21. Currently participating or have participated in an investigational study, other than&#xD;
             this study, within the past 60 days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Malca Chen-Zion, Ph.D</last_name>
    <phone>+972-73-7803607</phone>
    <email>malca@eye-yon.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Iris Shalev, DVM</last_name>
    <phone>+972-73-7803607</phone>
    <email>iris@eye-yon.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Akhali Mzera Eye Clinic</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Merab Dvali, Prof. MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Monika Zalinian, MD</last_name>
      <email>monikazalinyan@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>High Technology Medical Center, University Clinic</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Dvalishvili, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Anna Khokhiashvili, MD</last_name>
      <email>SOFI777@mail.ru</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>International Vision Correction Research Centre (IVCRC) Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gerd U. Auffarth, Prof. MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Raquel Willrich Amroussi, M.A.</last_name>
      <email>raquel.willrichamroussi@med.uni-heidelberg.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Dr Agarwal's Eye Hospital</name>
      <address>
        <city>Tirunelveli</city>
        <state>Tamil Nadu</state>
        <zip>627003</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Prof. Lional Raj, MD</last_name>
      <email>drlionalraj@dragarwal.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Modi Naftali, MD.</last_name>
      <email>m_naftali@rambam.health.gov.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Assuta HaShalom</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Israel Leshem, MD.</last_name>
      <email>israell@assuta.co.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amsterdam MC (AMC)</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ruth Lapid- Gortzak, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Monique Wezel</last_name>
      <email>m.wezel@amsterdamumc.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Georgia</country>
    <country>Germany</country>
    <country>India</country>
    <country>Israel</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 20, 2021</study_first_submitted>
  <study_first_submitted_qc>November 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Corneal edema</keyword>
  <keyword>Chronic corneal edema</keyword>
  <keyword>THE ENDOART®</keyword>
  <keyword>Artificial Endothelial layer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Corneal Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

